Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy
19 Setembro 2023 - 5:00PM
Praxis Bioresearch (“Praxis”), a biopharmaceutical company focused
on the discovery and development of therapeutics for chronic
neuropsychiatric and neurodegenerative disorders with an initial
focus on apathy in Alzheimer’s Disease, today announced the
appointment of Adam Levy to its Board of Directors (the “Board”).
Mr. Levy brings executive, financial and operational leadership
experience in biopharmaceuticals.
“We are excited to have Adam join our Board and support our
mission to improve the lives of patients with Alzheimer’s Disease,”
said Sandeep Patil, MD PhD, chief executive officer of Praxis
Bioresearch. “Adam brings an impressive track record of business
accomplishments and innovation that will greatly complement
our current Board’s experience as Praxis advances PRX-P4-003
further into clinical development.”
Mr. Levy has served as the Chief Financial Officer and Chief
Business Officer of Mineralys Therapeutics (Nasdaq: MLYS), a
clinical-stage biopharmaceutical company focused on developing
medicines to target hypertension, chronic kidney disease and other
diseases driven by abnormally elevated aldosterone since March
2022. Prior to Mineralys, he served as the Chief Financial Officer
at Sanifit Therapeutics, a clinical-stage biopharmaceutical company
focused on treatments for vascular calcification disorders, until
it was acquired by Vifor Pharma in January 2022. Prior to Sanifit,
he served as the Chief Business Officer at Brickell Biotech, where
he led the organization's financial operations transition as it
became a publicly listed company on the Nasdaq. Before joining
Brickell, Adam was the Chief Business Officer at miRagen
Therapeutics, Inc., where he had broad operational
responsibilities and led several business development transactions
and capital raises, including a listing on the Nasdaq. Previous to
his executive roles in biopharmaceuticals, Adam held multiple
investment banking positions at Bank of America, Merrill Lynch,
Jefferies and Wedbush. During his time as an investment banker, he
completed over $30 Billion in financing and M&A transactions
for his clients.
“Apathy afflicts as many as 70% of Alzheimer’s patients and
there are no approved therapies available,” said Adam Levy. “I am
looking forward to working with Sandeep and the Board as we advance
PRX-P4-003 into further clinical trials to potentially improve the
quality of life for millions of patients suffering with this
devastating disease.”
About Apathy in Alzheimer’s DiseaseApathy
is the most common noncognitive symptom in Alzheimer’s Disease,
affecting nearly 70% of the patients. Untreated apathy can lead to
a poor quality of life of the patient, rapid decline in cognition,
increased caregiver distress and may result in costly early
institutionalization.
About Praxis BioresearchPraxis Bioresearch,
Inc., is a biopharmaceutical company focused on the discovery and
development of therapeutics for chronic neuropsychiatric and
neurodegenerative disorders. Praxis’s lead development candidate is
PRX-P4-003, a novel prodrug stimulant designed to offer robust
clinical activity while reducing risk of side
effects. PRX-P4-003 is initially being developed for the
treatment of apathy in Alzheimer’s Disease. For more information
visit: www.praxisbioresearch.com.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/593ac505-b80d-46f3-8c0e-d65a196ebd0f
Contact:
info@praxisbioresearch.com
Mineralys Therapeutics (NASDAQ:MLYS)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Mineralys Therapeutics (NASDAQ:MLYS)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024